Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide

A recent study, published on Nature, in metastatic castration‑resistant prostate cancer (mCRPC) shows that a simple blood test can reveal important information about how the tumor is reprogramming its metabolism and how it responds to enzalutamide, a common androgen‑receptor‑targeting drug. Researchers analyzed the entire circulating “lipidome” (the full panel of fats and related molecules in plasma) in patients with mCRPC and compared them with men who did not have cancer. They found that men with mCRPC have a distinct lipid profile, with higher levels of monounsaturated fats and long‑chain phospholipids, changes that mirror what is seen in prostate cancer tissue itself, suggesting that the blood can indirectly reflect the tumor’s internal chemical activity.

When patients started treatment with enzalutamide, their plasma lipid pattern shifted noticeably. Total lipid levels and monounsaturated fats decreased, and the relative balance among phospholipids and sphingolipids changed, with a drop in ceramides and a rise in sphingomyelins. These shifts suggest that the drug is not only blocking the androgen receptor but also dampening the cancer’s ability to build new fatty‑acid–rich membranes needed for rapid growth and survival. At the time of radiographic progression, some of the monounsaturated fat levels began to return toward pre‑treatment values, hinting that the tumor might be reactivating certain metabolic programs that support resistance.

One of the most interesting findings is that the behavior of a specific sphingomyelin species, SM 18:1–18:1, after starting enzalutamide is linked to long‑term outcomes. Higher levels of this particular sphingomyelin in the blood during treatment were associated with better progression‑free survival and overall survival, even after adjusting for age, Gleason score, PSA response, and disease volume. This suggests that SM 18:1–18:1 may act as a kind of “metabolic signature” of favorable response, reflecting a healthier balance between different sphingolipids that are known to influence whether cancer cells survive or die.

For clinicians, these results reinforce the idea that lipid metabolism is not just a background process but an active player in how prostate cancer adapts to androgen‑receptor‑targeted therapy. They also open the door to using plasma lipidomics as a non‑invasive tool to monitor disease activity and treatment response, potentially helping to identify which patients are responding well at the metabolic level and which may be developing early resistance.

Source.